The Second Panel on Cost-Effectiveness in Health and Medicine was formed in 2012 to review the current status of the field of cost-effectiveness analysis and developed a new set of recommendations. Find out more about major changes made here. (Source: The Journal of the American Medical Association, […]
Do We Need Financial Transparency in Clinical Guidelines
Organizations that produce clinical practice guidelines and biomedical companies are often not in the habit of disclosing financial relationships. Can you say financial conflicts of interest? How big of a problem is this? See more here. (Source: […]
Guiding Practices for Patient-Centered Value Assessment
The National Pharmaceutical Council has developed Guiding Practices for Patient-Centered Value Assessment that include 28 specific elements, which are broken out into six key aspects of value assessments: the assessment process, methodology, benefits, costs, evidence, and dissemination and […]
ISPOR Task Force Reports on Multiple Criteria Decision Analysis
The first report from the ISPOR task force on uses of multiple criteria decision analysis (MCDA) in health care decision making has just recently been published in Value in Health. Take a closer look at this report here, and see what's in store for the second report. […]
New Value Based Guidelines Released for Prostate and Breast Cancers
Families USA and ICER recently released guidelines to help patients choose screening methods and treatments for prostate and breast cancers according to value. What has been the response of the American Society for Radiation Oncology (ASTRO)? Find out more here. (Source: Journal of Clinical […]
Learn More About ASCO Clinical Pathway Recommendations
The American Society for Clinical Oncology (ASCO) recently released a statement offering several recommendations to improve clinical pathways in oncology. Learn more about these recommended improvements here. (Source: Kelsey Lang, PhRMA, 1/18/16) […]
ASCO Endorses ACCP Guidelines for Small Cell Lung Cancer
After a 4-year literature review, the American Society of Clinical Oncology (ASCO) has officially endorsed the current American College of Chest Physicians (ACCP) guideline for the treatment of small cell lung cancer (SCLC). Find out more here. (Source: Journal of Clinical Pathways, 1/6/16) […]
ICER Releases Final Report on PCSK9 Use
The Institute for Clinical and Economic Review (ICER) recently posted the final report PCSK9 Inhibitors for Treatment of High Cholesterol: Effectiveness, Value, and Value-Based Price Benchmarks, along with its accompanying Action Guides to the New England Comparative Effectiveness Public Advisory […]
PCORI Releases New Guidelines for Research on Rare Diseases
The Patient-Centered Outcomes Research Institute (PCORI) recently released new guidance on research in rare disease. Download PDF here. (Source: pcori, 10/20/15) […]
Evidence Based Medicare Guidelines Embraced by Lawmakers
The CMS' 2016 Medicare Physician Fee Schedule is looking to decrease unnecessary imaging diagnostic tests in the Medicare system. Read more here. (Source: The Ripon Advance, 9/24/15) […]
What do Clinical Pathways Mean for Treatment Options?
A new survey from CancerCare found that the vast majority of surveyed patients diagnosed within the past five years had not heard of clinical pathways. Read more here and see the infographic, What do Clinical Pathways Mean for Treatment Options?. (Source: Holly Campbell, PhRMA, 9/16/15) […]
New Oncology Pricing Tool – A Threat to Drugmakers?
A new tool from The National Comprehensive Cancer Network (NCCN), aims to provide a clearer picture of the relative value of medication options and shift demand away from less effective treatments. Find out more here. (Source: First Report Managed Care, 8/25/15) […]
Why Are UK General Practitioners Ignoring NICE Guidelines?
The National Institute for Health and Care Excellence (NICE) is becoming increasingly detached from day-to-day general practice. More than 70% of English and Welsh GPs admit to departing from NICE recommended practice at least once a month and 10 % say they do so on a daily basis. Will NICE be able […]
How An Online Group Of Lung Cancer Survivors Changed Treatment Guidelines
Ever question the power of the few? In the words of Margaret Mead, "Never doubt that a group of thoughtful, committed citizens can change the world; indeed, it's the only thing that ever has." That is exactly what this story of an online group of Lung Cancer survivors is all about. They saw […]
CTAF Releases Final Report On Newest Hep C Treatments
The Institute for Clinical and Economic Review (ICER) has released the final California Technology Assessment Forum (CTAF) report and three complimentary Action Guides. Read more here. (Source: Institute for Clinical and Economic Review, 2/27/15) […]
ISPOR’s Outcomes Research Guideline Index
The objective of ISPOR's Outcomes Research Guideline Index is to improve state-of-the-art methods in outcomes research and gain acceptance of their use in research and decision making. More information available here. (Source: ISPOR, 2015) […]
Optimize The Reporting of Health Economic Evaluations With CHEERS!
ISPOR's Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force set out to provide recommendations to optimize the reporting of health economic evaluations. The Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement is an attempt to consolidate […]
How Informed Should Informed Consent Be?
The FDA has recently issued an updated guidance document on obtaining informed consent for clinical trials. The majority of the document content appears to remain unchanged, specifying in greater detail how consent should be obtained. The one exception being a section urging that trial participants […]
ACC/AHA Practice Guideline
This is a report of the American College of Cardiology (ACC)/American Heart Association (AHA) task force on performance measures and task force on practice guidelines. Read more here. (Source: AHA, Circulation, 3/27/14). […]
Familiar With The Latest FDA Biosimilar Guidelines?
The FDA recently released a guidance document on the use of clinical pharmacology data to show equivalence to an approved biologic drug. Learn more here. (Source: SmartBrief,5/14/14). […]
Pharmacoeconomic Guidelines Around The World
Pharmacoeconomic (PE) guidelines can be used as a standard for preparation of studies to be included in application for reimbursement, a guide for designing and conducting a study, or a template for evaluating the economic study reports. More information available here. (Source: ISPOR) […]
Compendium of Policies, Guidelines and Procedures – Issued to Promote Awareness and Facilitate Compliance
The Compendium of Policies, Guidelines and Procedures outlines the process that Board Staff review the prices of patented drug products, and proceed when a price appears to be excessive. This Compendium has been issued to promote awareness and facilitate compliance. More information here. […]
Ever Wonder About Patented Drug Prices?
The Compendium of Policies, Guidelines and Procedures outlines the process that Board Staff review the prices of patented drug products, and proceed when a price appears to be excessive. This Compendium has been issued to promote awareness and facilitate compliance. More information here. (Source: […]
Are JAMA Guidelines Likely To Harm Patients?
JAMA published the long-awaited Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure-8 (JNC-8)guidelines December 18, 2013. In this article, David Cundiff, MD calls for states that the JNC-8 authors ignored evidence and have put forth guidelines that […]
The Evolution of Product Evaluation
A DIY Project: When is a Structured Review Sufficient?
The conceptual differences between a systematic and a structured review can be nuanced. The time and cost difference, however, is quite clear. How, then, can an investigator decide which to choose? A short DIY guide with an example shows you how. Read full article, on page 17. (Source: Evidera, […]
